# RECOVAC - Long Term Efficacy and Safety of COVID-19 (SARS-CoV-2) Vaccination in Kidney Disease Patients

> **NCT04841785** · — · COMPLETED · sponsor: **University Medical Center Groningen** · enrollment: 4868 (actual)

## Conditions studied

- Covid19
- SARS-CoV Infection
- Chronic Kidney Diseases

## Interventions

- **DIAGNOSTIC_TEST:** mailer-based finger-prick

## Key facts

- **NCT ID:** NCT04841785
- **Lead sponsor:** University Medical Center Groningen
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-22
- **Primary completion:** 2021-11-30
- **Final completion:** 2023-12-18
- **Target enrollment:** 4868 (ACTUAL)
- **Last updated:** 2024-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04841785

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04841785, "RECOVAC - Long Term Efficacy and Safety of COVID-19 (SARS-CoV-2) Vaccination in Kidney Disease Patients". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04841785. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*